Barely Significant
← all excerpts

Comparative efficacy and safety of cabazitaxel versus other taxanes: a systematic review and meta-analysis.

Syst Rev · 2025 · PMC12577412 · PMID 41174820

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

borderline significantp = 0.05actually significant
Lastly, thrombocytopenia risk was non-significant for cabazitaxel versus other taxanes (RR = 1.47, 95% CI 0.76–2.83; I 2 = 0%) but borderline significant for C25 versus C20 (RR = 1.70, 95% CI 1.00–2.89; p = 0.05) (Fig. 9 ).

also in 9,411 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.